Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life

Prostate Cancer and Prostatic Diseases volume 13, pages 97–101 (2010)Cite this article

Abstract

Therapeutic strategy remains unclear with no clear consensus for men with high-risk prostate cancer (PCa) after radical prostatectomy. We aimed to evaluate into a prospective randomized trial the effectiveness and feasibility of adjuvant weekly paclitaxel combined with androgen deprivation therapy (ADT) in these patients. A total of 47 patients with high-risk PCa were randomized 6 weeks after radical prostatectomy: ADT alone versus combination of ADT and weekly paclitaxel. Toxicity, quality-of-life and functional results were compared between the two arms. All 23 patients completed eight cycles of paclitaxel. Toxicity was predominantly of grade 1–2 severity. There were no differences in EORTC QLQ-C30 scores between the two groups and between baseline and last assessment at 24 months after surgery. Urinary continence was complete at 1 year after surgery for all patients and no significant differences were noted at each assessment between the two groups. The interim analysis of this trial confirms the feasibility of weekly paclitaxel in combination with ADT in men at high-risk PCa with curative intent. This adjuvant combined therapy does not alter quality-of-life and continence recovery after surgery plus ADT. A larger cohort is awaited to determine the oncological outcomes of this strategy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics. CA Cancer J Clin 2009; 59: 225–249.

    Article  PubMed  Google Scholar 

  2. Kattan MW, Wheeler TM, Scardino PT . Postoperative nomogram for disease recurrence after prostatectomy for prostate cancer. J Clin Oncol 199; 17: 1499–1507.

    Article  Google Scholar 

  3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ . Cancer progression and survival rates following radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172: 910–914.

    Article  PubMed  Google Scholar 

  4. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.

    Article  CAS  Google Scholar 

  5. Messing E M, Manola J, Sarosdy M, Wilding G, Crawford E D, Trump D . Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781–1788.

    Article  CAS  PubMed  Google Scholar 

  6. Messing E M, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472–479.

    Article  PubMed  Google Scholar 

  7. McLeod D G, Iversen P, See W A, Morris T, Armstrong J, Wirth M P . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247–254.

    Article  PubMed  Google Scholar 

  8. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J et al. Long-term followup of a randomized trail of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791–794.

    Article  CAS  PubMed  Google Scholar 

  9. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol 2009; 181: 956–962.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–1520.

    Article  CAS  PubMed  Google Scholar 

  11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502–1512.

    Article  CAS  PubMed  Google Scholar 

  12. Kibel A S, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007; 177: 1777–1781.

    Article  PubMed  Google Scholar 

  13. Cetnar JP, Malkowicz SB, Palmer SC, Wein AJ, Vaughn DJ . Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer. Urology 2008; 71: 942–946.

    Article  PubMed  Google Scholar 

  14. Montgomery B, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S et al. Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy After Prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology 2008; 72: 474–480.

    Article  PubMed  Google Scholar 

  15. Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE et al. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer 2007; 110: 2628–2639.

    Article  CAS  PubMed  Google Scholar 

  16. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 1138–1142.

    Article  PubMed  Google Scholar 

  17. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2004; 11: 5233–5240.

    Article  Google Scholar 

  18. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329–2335.

    Article  CAS  Google Scholar 

  19. Sokoloff MH, Rinker-Schaeffer CW, Chung LWK, Brendler CB . Adjunctive therapy for men with high risk localized and locally advanced prostate cancer: targeting disseminated tumor cells. J Urol 2004; 172: 2539–2544.

    Article  PubMed  Google Scholar 

  20. Roth B J, Yeap B Y, Wilding G, Kasimis B, McLeod D, Loehrer PJ . Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993; 72: 2457–2460.

    Article  PubMed  Google Scholar 

  21. Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000; 89: 431–436.

    Article  CAS  PubMed  Google Scholar 

  22. Salomon L, Anastasiadis AG, Katz R, De La Taille A, Saint F, Vordos D et al. Urinary continence and erectile function: a prospective evaluation of functional results after laparoscopic prostatectomy. Eur Urol 2002; 42: 338–343.

    Article  PubMed  Google Scholar 

  23. Salomon L, Saint F, Anastasiadis AG, Sèbe P, Chopin D, Abbou CC . Combined reporting of cancer control and functional results of radical prostatectomy. Eur Urol 2003; 44: 656–660.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

With the support of Takeda, Ipsen Biotech and Bristol-Myers-Squibb.

Author information

Authors and Affiliations

  1. INSERM U955 Eq07 Department of Urology, APHP, CHU Henri Mondor, Créteil, France

    G Ploussard, B Paule, L Salomon, S Terry, D Vordos, A Hoznek, F Vacherot, C-C Abbou & A de la Taille

  2. INSERM U955 Eq07 Department of Pathology, APHP, CHU Henri Mondor, Créteil, France

    Y Allory

  3. INSERM U955 Eq07 Department of Oncology, APHP, CHU Henri Mondor, Créteil, France

    S Culine

Authors
  1. G Ploussard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Paule
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Salomon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Allory
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Terry
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Vordos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Hoznek
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Vacherot
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C-C Abbou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Culine
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A de la Taille
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A de la Taille.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ploussard, G., Paule, B., Salomon, L. et al. Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life. Prostate Cancer Prostatic Dis 13, 97–101 (2010). https://doi.org/10.1038/pcan.2009.51

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.51

Keywords

This article is cited by

Search

Advanced search

Quick links